Withdrawing Drugs in the U.S. Versus Other Countries Benson Ninan

Total Page:16

File Type:pdf, Size:1020Kb

Withdrawing Drugs in the U.S. Versus Other Countries Benson Ninan Volume 3 | Number 3 Article 87 2012 Withdrawing Drugs in the U.S. Versus Other Countries Benson Ninan Albert I. Wertheimer Follow this and additional works at: http://pubs.lib.umn.edu/innovations Recommended Citation Ninan B, Wertheimer AI. Withdrawing Drugs in the U.S. Versus Other Countries. Inov Pharm. 2012;3(3): Article 87. http://pubs.lib.umn.edu/innovations/vol3/iss3/6 INNOVATIONS in pharmacy is published by the University of Minnesota Libraries Publishing. Commentary POLICY Withdrawing Drugs in the U.S. Versus Other Countries Benson Ninan, Pharm.D.1 and Albert I Wertheimer, PhD, MBA2 1Pharmacy Intern, Rite Aid Pharmacies, Philadelphia, PA and 2Temple University School of Pharmacy, Philadelphia PA Key Words: Drug withdrawals, dangerous drugs, UN Banned Drug list Abstract Since 1979, the United Nations has maintained a list of drugs banned from sale in member countries. Interestingly, there are a number of pharmaceuticals on the market in the USA that have been banned elsewhere and similarly, there are some drug products that have been banned in the United States, but remain on the market in other countries. This report provides a look into the policies for banning drug sales internationally and the role of the United Nations in maintaining the master list for companies and countries to use for local decision guidance. Background recently updated issue is the fourteenth issue, which contains At present, one of the leading causes of death in the U.S. is data on 66 new products with updated/new information on believed to be adverse drug reactions.1-14 More than 20 22 existing products. An update of the fourteenth issue was million patients have taken at least 1 of the 5 drugs published in 2010 adding 99 more products to the List by the withdrawn from the market between September 1997 and actions of 38 governments.3 September 1998. Seven drugs that were approved in 1993 and were withdrawn shortly later have contributed to 1002 In 1985 the United Nations Secretariat, in conjunction with deaths.14 A study in 2002, showed that out of the 548 drugs the World Health Organization (WHO) and the United Nations that were approved in the U.S. between 1975-1999, fifty six Environment Program (UNEP) met at the first inter-agency (10.2 %) of them required a new black box warning or were meeting and executed the first review of the List. The review withdrawn.12 Thus, it is very important that the consumer as outlined key points such as arrangements for the preparation well as the practitioner become aware of dangerous drugs. of future issues, the need for criteria for determining the inclusion of products, the question of the legal and public In 1979 the United Nations General Assembly first brought up health context of regulatory actions that were not included in the question of establishing a list of banned pharmaceutical the first issue of the List and the treatment of commercial products that could be exchanged between nations. Under data.2 Ever since then the List has been updated annually resolution 37/137 (Annex I) of December 17 1982, the making the information available to users through direct General Assembly requested the Secretary-General to internet access. organize the Consolidated List of Products Whose Consumption and/or Sale Have Been Banned, Withdrawn, Introduction Severely restricted or Not Approved by Governments. The List Since 1995 the List was divided into two separate issues, one is a continuing effort by the United Nations to circulate focusing on pharmaceuticals and the other on chemicals, information on products that are harmful to health and the which are published in alternate years. The pharmaceuticals environment.2 are further separated into monocomponent products, combination products and group products.2 This paper will The first issue of the List covered less than 500 products only focus on the 151 monocomponent pharmaceuticals that regulated by 60 governments. The fifth issue which covered were withdrawn and why they were withdrawn by the U.N. both pharmaceuticals and chemicals, included over 700 and by specific countries such as the USA, Japan, UK, Sweden products regulated by 94 governments. By the eleventh and and Australia. twelfth editions, the List had grown to include more than 1100 products regulated by 115 states.2 At present the most More specifically, this paper will compare the drugs banned in the U.S. versus the drugs banned in other prominent countries. Do we have similar policies on which drugs to Corresponding author: Albert I Wertheimer, PhD, MBA withdraw or, does the U.S. act on its own when it comes to Temple University School of Pharmacy drug withdrawal? Philadelphia PA 1 9140; [email protected] While the U.N. may outlaw a certain drug, it is possible that the banned drug may be still available in certain countries. In http://z.umn.edu/INNOVATIONS 2012, Vol. 3, No. 3, Article 87 INNOVATIONS in pharmacy 1 Commentary POLICY addition, this paper will investigate any lag time that may benefit that drug companies/ government get from keeping a occur between the issue date of withdrawal by the U.N. and drug on the market. An example of a drug that has continued the actual date it was removed from the specific country. It is to be kept on the market is the anti-diabetic drug, important to note that if a product is not listed as regulated rosiglitazone (Avandia). A drug might also be kept on the by a country it does not necessarily mean that it is permitted market in one country because it has a legitimate medical in the country. It is highly possible that some information has use, while in another country it may not be used medically not been communicated to the U.N.2 as well. and therefore is banned. For example, flunitrazepam, commonly known as the date rape drug “roofies”, is used for Drugs Banned in the U.S. the treatment of insomnia in many European countries. In the United States of America, The Center for Drug However, the FDA has not approved the use of flunitrazepam Evaluation and Research (CDER) a part of the U.S. Food and and it has deemed it an illegal substance.2 Drug Administration (FDA) is in charge of evaluating new drugs for safety and effectiveness before they may be sold. Figure 1 also shows that only 19% of drugs were banned After the drugs are on the market, CDER acts as a watchdog, worldwide. This shows the lack of agreement on which drugs monitoring for any side effects and for any unexpected health should be banned globally. It seems as if drugs that were risks. Sometimes drugs have to be withdrawn from the banned worldwide had to have severe fatal adverse effects market due to severe unwanted side effects that may be before they reached the eyes of the entire world. Drugs such fatal. In 2005, new molecular entities (NME) such as as Fen-Fen which contained fenfluramine and phentermine valdecoxib, pemoline, and technetium (99m Tc) fanolesomab were mainly removed after 20 years in the U.S. market due to were all removed due to increased risk of serious adverse a lawsuit which totaled over $13 billion in legal damages and effects. Valdecoxib, a COX-2 selective inhibitor was removed of course potential fatal pulmonary hypertension and heart from the market due to increased risk of skin reactions and valve problems.10 Both fenfluramine and its d-enantiomer, cardiovascular events. Likewise pemoline, a CNS stimulant dexafluramine (Redux) were withdrawn in September 1997 used for treatment of ADHD was removed because of fatal worldwide. The second drug that made up Fen-fen, hepatoxicity2 (See appendix for more drugs that were phentermin was banned in Sweden and the United Kingdom removed in the U.S., Internationally, and worldwide). in 1981 and 2000 respectively. However, it is still marketed widely in the U.S. 2 Figure 1 shows the percentage of the 151 drugs we studied Figure 2. that were removed in the U.S. compared to the drugs that were removed internationally and worldwide. Figure 1. Banned Internationally 17% but available in U.S. Percentage of Drugs Banned Drugs Banned Worldwide 19% US Banned but available 9% Internationally Internationally Banned 79% Drugs 0% 5% 10% 15% 20% US Banned Drugs 67% Figure 2 compares the drugs that were banned in the U.S. but are available internationally versus the drugs that are banned 0% 20% 40% 60% 80% 100% internationally but are available in the U.S. It shows that 9 % of the drugs banned by the U.S. are available in the Only 67 % of the 151 drugs that were on the List were banned international market. On the other hand, of the drugs banned by the U.S, while internationally 79 % were banned. This internationally, 17 % are available in the U.S. This goes to shows clearly that the U.S is not in complete agreement with show again that the policies of the U.S. may tend to be the other countries on which drugs should be banned. There different than the rest of the World. Of the 17 % are many reasons why the policies of the U.S may differ from internationally banned drugs, three of the drugs are from the the international world. One reason might be a monetary same class of drugs, the barbiturates. In Sweden, barbiturates http://z.umn.edu/INNOVATIONS 2012, Vol. 3, No. 3, Article 87 INNOVATIONS in pharmacy 2 Commentary POLICY such as amobarbital, hexobarbital, pentobarbital and Only 9% percent of drugs banned by the U.S.
Recommended publications
  • AHFS Pharmacologic-Therapeutic Classification System
    AHFS Pharmacologic-Therapeutic Classification System Abacavir 48:24 - Mucolytic Agents - 382638 8:18.08.20 - HIV Nucleoside and Nucleotide Reverse Acitretin 84:92 - Skin and Mucous Membrane Agents, Abaloparatide 68:24.08 - Parathyroid Agents - 317036 Aclidinium Abatacept 12:08.08 - Antimuscarinics/Antispasmodics - 313022 92:36 - Disease-modifying Antirheumatic Drugs - Acrivastine 92:20 - Immunomodulatory Agents - 306003 4:08 - Second Generation Antihistamines - 394040 Abciximab 48:04.08 - Second Generation Antihistamines - 394040 20:12.18 - Platelet-aggregation Inhibitors - 395014 Acyclovir Abemaciclib 8:18.32 - Nucleosides and Nucleotides - 381045 10:00 - Antineoplastic Agents - 317058 84:04.06 - Antivirals - 381036 Abiraterone Adalimumab; -adaz 10:00 - Antineoplastic Agents - 311027 92:36 - Disease-modifying Antirheumatic Drugs - AbobotulinumtoxinA 56:92 - GI Drugs, Miscellaneous - 302046 92:20 - Immunomodulatory Agents - 302046 92:92 - Other Miscellaneous Therapeutic Agents - 12:20.92 - Skeletal Muscle Relaxants, Miscellaneous - Adapalene 84:92 - Skin and Mucous Membrane Agents, Acalabrutinib 10:00 - Antineoplastic Agents - 317059 Adefovir Acamprosate 8:18.32 - Nucleosides and Nucleotides - 302036 28:92 - Central Nervous System Agents, Adenosine 24:04.04.24 - Class IV Antiarrhythmics - 304010 Acarbose Adenovirus Vaccine Live Oral 68:20.02 - alpha-Glucosidase Inhibitors - 396015 80:12 - Vaccines - 315016 Acebutolol Ado-Trastuzumab 24:24 - beta-Adrenergic Blocking Agents - 387003 10:00 - Antineoplastic Agents - 313041 12:16.08.08 - Selective
    [Show full text]
  • (19) United States (12) Patent Application Publication (10) Pub
    US 20130289061A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0289061 A1 Bhide et al. (43) Pub. Date: Oct. 31, 2013 (54) METHODS AND COMPOSITIONS TO Publication Classi?cation PREVENT ADDICTION (51) Int. Cl. (71) Applicant: The General Hospital Corporation, A61K 31/485 (2006-01) Boston’ MA (Us) A61K 31/4458 (2006.01) (52) U.S. Cl. (72) Inventors: Pradeep G. Bhide; Peabody, MA (US); CPC """"" " A61K31/485 (201301); ‘4161223011? Jmm‘“ Zhu’ Ansm’ MA. (Us); USPC ......... .. 514/282; 514/317; 514/654; 514/618; Thomas J. Spencer; Carhsle; MA (US); 514/279 Joseph Biederman; Brookline; MA (Us) (57) ABSTRACT Disclosed herein is a method of reducing or preventing the development of aversion to a CNS stimulant in a subject (21) App1_ NO_; 13/924,815 comprising; administering a therapeutic amount of the neu rological stimulant and administering an antagonist of the kappa opioid receptor; to thereby reduce or prevent the devel - . opment of aversion to the CNS stimulant in the subject. Also (22) Flled' Jun‘ 24’ 2013 disclosed is a method of reducing or preventing the develop ment of addiction to a CNS stimulant in a subj ect; comprising; _ _ administering the CNS stimulant and administering a mu Related U‘s‘ Apphcatlon Data opioid receptor antagonist to thereby reduce or prevent the (63) Continuation of application NO 13/389,959, ?led on development of addiction to the CNS stimulant in the subject. Apt 27’ 2012’ ?led as application NO_ PCT/US2010/ Also disclosed are pharmaceutical compositions comprising 045486 on Aug' 13 2010' a central nervous system stimulant and an opioid receptor ’ antagonist.
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • Amfepramone (Diethylpropion) Elisa Kit Instructions Product #182119, 182116 & 182113 Forensic Use Only
    Neogen Corporation 944 Nandino Blvd., Lexington KY 40511 USA 800/477-8201 USA/Canada | 859/254-1221 Fax: 859/255-5532 | E-mail: [email protected] | Web: www.neogen.com/Toxicology AMFEPRAMONE (DIETHYLPROPION) ELISA KIT INSTRUCTIONS PRODUCT #182119, 182116 & 182113 FORENSIC USE ONLY INTENDED USE: For the determination of trace quantities of Amfepramone (Diethylpropion) and/or other metabolites in human samples. DESCRIPTION Neogen Corporation’s Amfepramone (Diethylpropion) ELISA (Enzyme-Linked Immunosorbent Assay) test kit is a qualitative one-step kit designed for use as a screening device for the detection of drugs and/or their metabolites. The kit was designed for screening purposes and is intended for forensic use only. It is recommended that all suspect samples be confirmed by a quantitative method such as gas chromatography/mass spectrometry (GC/MS). ASSAY PRINCIPLE The Neogen forensic drug detection ELISA is a solid phase immunoassay designed to detect drugs of abuse for forensic application. The test is performed in microwells coated with a high affinity capture antibody. A control or sample is added to the wells followed by an enzyme conjugate. During the following incubation period, the enzyme conjugate competes with the drug in the sample for binding sites on the antibody coated well. After a wash step to remove any unbound material, substrate is added for the color development process. Acid stop solution is added to discontinue the enzyme-substrate reaction. The color intensity is inversely proportional to the amount of drug present in the sample. Therefore, those samples which contain the drug will inhibit binding of the enzyme conjugate to the capture antibody resulting in less color than the negative control.
    [Show full text]
  • Partial Agreement in the Social and Public Health Field
    COUNCIL OF EUROPE COMMITTEE OF MINISTERS (PARTIAL AGREEMENT IN THE SOCIAL AND PUBLIC HEALTH FIELD) RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies, and superseding Resolution AP (82) 2) AND APPENDIX I Alphabetical list of medicines adopted by the Public Health Committee (Partial Agreement) updated to 1 July 1988 APPENDIX II Pharmaco-therapeutic classification of medicines appearing in the alphabetical list in Appendix I updated to 1 July 1988 RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (superseding Resolution AP (82) 2) (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies) The Representatives on the Committee of Ministers of Belgium, France, the Federal Republic of Germany, Italy, Luxembourg, the Netherlands and the United Kingdom of Great Britain and Northern Ireland, these states being parties to the Partial Agreement in the social and public health field, and the Representatives of Austria, Denmark, Ireland, Spain and Switzerland, states which have participated in the public health activities carried out within the above-mentioned Partial Agreement since 1 October 1974, 2 April 1968, 23 September 1969, 21 April 1988 and 5 May 1964, respectively, Considering that the aim of the Council of Europe is to achieve greater unity between its members and that this
    [Show full text]
  • SUPPLEMENTARY TABLES Compounds Pharmacology
    SUPPLEMENTARY TABLES Table S1. Pharmacology of repositioned compounds. Compounds Pharmacology Bithionol [18] • Halogenated anti-infective agent that is used against trematode and cestode infestations. • Inhibits human soluble adenylyl cyclase Tacrolimus [19] • Inhibits calcineurin phosphatase activity, thus decreases cytokine production. • Exhibits immunosuppressive activity (more potent than cyclosporine). • Prevents T-lymphocyte activation in response to antigenic or mitogenic stimulation. Floxuridine [20] • Fluorinated pyrimidine monophosphate analog of 5-fluoro-2'-deoxyuridine-5'- phosphate (FUDR-MP) with antineoplastic activity. • Inhibits thymidylate synthase, thus disrupting DNA synthesis. • Fluorouracil, the metabolized product, incorporates into RNA, which prevents the utilization of uracil in RNA synthesis. Auranofin [21] • Inhibits the activity of mitochondrial thioredoxin reductase (TrxR) by interacting with selenocysteine within the redox-active domain. • Induces mitochondrial oxidative stress, thus resulting in the induction of apoptosis. • Inhibits the JAK1/STAT3 signaling pathway, hence suppresses the expression of immune factors involved in inflammation. Drospirenone [22] • Possesses progestational and anti- mineralocorticoid activity. • Binds to the progesterone receptor, resulting in a suppression/inhibition of LH activity and ovulation (oral contraceptive). Perhexiline [23] • Binds to the mitochondrial enzyme carnitine palmitoyltransferase (CPT)-1 and CPT-2. • Shifts myocardial substrate utilization, viz., shifting from long chain fatty acids to carbohydrates via the inhibition of CPT-1 and CPT-2, thus used for the therapy in patients with ischaemia. • May cause neuropathy and hepatitis. Toremifene [24] • Selectively modulates estrogen receptors by competitively binds to the receptors, thus interferes with estrogen activity. Aspirin • Non-steroidal anti-inflammatory agent. (Acetylsalicylic • Binds to/acetylates serine residues in acid) [25] cyclooxygenases. • Decreased synthesis of prostaglandin, platelet aggregation, and inflammation.
    [Show full text]
  • Pharmaceuticals Appendix
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ADAPALENE 106685-40-9 ABANOQUIL 90402-40-7 ADAPROLOL 101479-70-3 ABECARNIL 111841-85-1 ADEMETIONINE 17176-17-9 ABLUKAST 96566-25-5 ADENOSINE PHOSPHATE 61-19-8 ABUNIDAZOLE 91017-58-2 ADIBENDAN 100510-33-6 ACADESINE 2627-69-2 ADICILLIN 525-94-0 ACAMPROSATE 77337-76-9 ADIMOLOL 78459-19-5 ACAPRAZINE 55485-20-6 ADINAZOLAM 37115-32-5 ACARBOSE 56180-94-0 ADIPHENINE 64-95-9 ACEBROCHOL 514-50-1 ADIPIODONE 606-17-7 ACEBURIC ACID 26976-72-7 ADITEREN 56066-19-4 ACEBUTOLOL 37517-30-9 ADITOPRIME 56066-63-8 ACECAINIDE 32795-44-1 ADOSOPINE 88124-26-9 ACECARBROMAL 77-66-7 ADOZELESIN 110314-48-2 ACECLIDINE 827-61-2 ADRAFINIL 63547-13-7 ACECLOFENAC 89796-99-6 ADRENALONE 99-45-6 ACEDAPSONE 77-46-3 AFALANINE 2901-75-9 ACEDIASULFONE SODIUM 127-60-6 AFLOQUALONE 56287-74-2 ACEDOBEN 556-08-1 AFUROLOL 65776-67-2 ACEFLURANOL 80595-73-9 AGANODINE 86696-87-9 ACEFURTIAMINE 10072-48-7 AKLOMIDE 3011-89-0 ACEFYLLINE CLOFIBROL 70788-27-1
    [Show full text]
  • (19) United States (12) Patent Application Publication (10) Pub
    US 20130210835A1 (19) United States (12) Patent Application Publication (10) Pub. N0.2 US 2013/0210835 A1 Mitchell (43) Pub. Date: Aug. 15, 2013 (54) PHARMACEUTICAL COMPOSITIONS Publication Classi?cation (75) Inventor: Odes W. Mitchell; Arlington, TX (U S) (51) Int. Cl. A61K31/137 (2006.01) _ A611; 31/4402 (2006.01) (73) Ass1gnee: GM PHARMACEUTICAL, INC, A61K 31/485 (200601) Arhngton, TX (Us) A611; 31/09 (2006.01) _ A611; 31/495 (2006.01) (21) App1.No.. 13/703,584 A61K31/505 (200601) 22 PCT P1 d: J .13 2011 (52) us Cl ( ) 1e “n ’ CPC ........... .. A611; 31/137 (2013.01); A611;31/495 (86) PCT NO. PCT/“11,4031 (2013.01); A611;31/505 (2013.01); A611; 31/485 (2013.01); A611; 31/09 (2013.01); § 371 (0)0). A611;31/4402 (2013.01) (2), (4) Date: Feb- 2, 2013 USPC .... .. 514/255.04; 564/355; 514/653; 544/396; 544/332; 514/275; 546/74; 514/289; 514/282; Related US. Application Data 514657; 514652 (60) Provisional application No. 61/354,061; ?led on Jun. (57) ABSTRACT 11; 2010; provisional application No. 61/354,057; A composition of an antitussive; a decongestant; or an anti ?led on Jun. 11; 2010; provisional application No. histamine to treat respiratory and oral pharyngeal congestion 61/354,053; ?led on Jun. 11,2010. and related symptoms in a patient. US 2013/0210835 A1 Aug. 15,2013 PHARMACEUTICAL COMPOSITIONS mucus build-up to clear congestion in the air passages. Symp toms due to allergies or allergens are often treated With an CROSS-REFERENCES TO RELATED antihistamine.
    [Show full text]
  • ROS) in Cisplatin Chemotherapy: a Focus on Molecular Pathways and Possible Therapeutic Strategies
    molecules Review Elucidating Role of Reactive Oxygen Species (ROS) in Cisplatin Chemotherapy: A Focus on Molecular Pathways and Possible Therapeutic Strategies Sepideh Mirzaei 1, Kiavash Hushmandi 2, Amirhossein Zabolian 3, Hossein Saleki 3 , Seyed Mohammad Reza Torabi 3 , Adnan Ranjbar 3, SeyedHesam SeyedSaleh 4, Seyed Omid Sharifzadeh 3, Haroon Khan 5 , Milad Ashrafizadeh 6,7 , Ali Zarrabi 7 and Kwang-seok Ahn 8,* 1 Department of Biology, Faculty of Science, Islamic Azad University, Science and Research Branch, Tehran 1477893855, Iran; [email protected] 2 Department of Food Hygiene and Quality Control, Division of Epidemiology, Faculty of Veterinary Medicine, University of Tehran, Tehran 1417466191, Iran; [email protected] 3 Young Researchers and Elite Club, Tehran Medical Sciences, Islamic Azad University, Tehran 1477893855, Iran; [email protected] (A.Z.); [email protected] (H.S.); [email protected] (S.M.R.T.); [email protected] (A.R.); [email protected] (S.O.S.) Citation: Mirzaei, S.; Hushmandi, K.; 4 Student Research Committee, Iran University of Medical Sciences, Tehran 1449614535, Iran; Zabolian, A.; Saleki, H.; Torabi, [email protected] 5 S.M.R.; Ranjbar, A.; SeyedSaleh, S.; Department of Pharmacy, Abdul Wali Khan University, Mardan 23200, Pakistan; [email protected] 6 Sharifzadeh, S.O.; Khan, H.; Faculty of Engineering and Natural Sciences, Sabanci University, Orta Mahalle, Üniversite Caddesi No. 27, Orhanlı, Tuzla, Istanbul 34956, Turkey; milad.ashrafi[email protected] Ashrafizadeh, M.; et al. Elucidating 7 Sabanci University Nanotechnology Research and Application Center (SUNUM), Tuzla, Role of Reactive Oxygen Species Istanbul 34956, Turkey; [email protected] (ROS) in Cisplatin Chemotherapy: A 8 Department of Science in Korean Medicine, College of Korean Medicine, Kyung Hee University, Focus on Molecular Pathways and Seoul 02447, Korea Possible Therapeutic Strategies.
    [Show full text]
  • AGENDA Friday, September 9, 2016 7:00 A.M
    Needham Board of Health AGENDA Friday, September 9, 2016 7:00 a.m. – 9:00 a.m. Charles River Room – Public Services Administration Building 500 Dedham Avenue, Needham MA 02492 • 7:00 to 7:05 - Welcome & Review of Minutes (July 29 & August 29) • 7:05 to 7:30 - Director and Staff Reports (July & August) • 7:30 to 7:45 - Discussion about Proposed Plastic Bag Ban Christopher Thomas, Needham Resident • 7:45 to 7:50 - Off-Street Drainage Bond Discussion & Vote • 7:50 to 8:00 - Update on Wingate Pool Variance Application * * * * * * * * * * * * * Board of Health Public Hearing • 8:00 to 8:40 - Hearing for Proposed New or Amended BOH Regulations o Body Art o Synthetic Marijuana o Drug Paraphernalia • 8:40 to 8:50 - Board Discussion of Policy Positions • Other Items (Healthy Aging, Water Quality) • Next Meeting Scheduled for Friday October 14, 2016 • Adjournment (Please note that all times are approximate) 1471 Highland Avenue, Needham, MA 02492 781-455-7500 ext 511 (tel); 781-455-0892 (fax) E-mail: [email protected] Web: www.needhamma.gov/health NEEDHAM BOARD OF HEALTH July 29, 2016 MEETING MINUTES PRESENT: Edward V. Cosgrove, PhD, Chair, Jane Fogg, Vice-Chair, M.D., and Stephen Epstein, M.D STAFF: Timothy McDonald, Director, Donna Carmichael, Catherine Delano, Maryanne Dinell, Tara Gurge GUEST: Kevin Mulkern, Aquaknot Pools, Inc., Keith Mulkern, Aquaknot Pools, Inc., David Friedman, Wingate, Paul Humphreys, Michael Tomasello, Callahan, Inc. CONVENE: 7:00 a.m. – Public Services Administration Building (PSAB), 500 Dedham Avenue, Needham MA 02492 DISCUSSION: Call To Order – 7:06 a.m. – Dr. Cosgrove, Chairman APPROVE MINUTES: Upon motion duly made and seconded, the minutes of the BOH meeting of June 17, 2016 were approved as submitted.
    [Show full text]
  • La Hepatotoxicidad Del Droxicam
    Vol. 6, n.º 3 julio - septiembre 1993 butlletí groc Institut Català de Farmacologia Universitat Autònoma de Barcelona La hepatotoxicidad del droxicam Los antiinflamatorios no esteroides (AINE) pue- vía oral a animales de experimentación. 15 Cuando den producir alteraciones hepáticas, que van se disuelve en agua y en medio ácido, así co m o desde aumentos leves, transitorios y subclínicos en el quimo gástrico, se hidroliza inmediatamente de los enzimas hepáticos hasta cuadros bien es- a piroxicam y, según el laboratorio fabricante, se tablecidos de hepatitis citolítica, colostásica o absorbe en forma de piroxicam.16 De hecho, la mixta e, incluso, cuadros de hepatitis crónica. administración de droxicam a animales de labora- to r i o 16 y a seres humanos17 no da lugar a concen- No se conoce exactamente la frecuencia de es- traciones pIasmáticas detectables de droxicam,16 tas reacciones de hepatotoxicidad, pero parece sino de piroxicam. No obstante, se ha podido ser muy baja.1 No obstante, el potencial hepato- comprobar recientemente que tras la administra- tóxico no parece ser el mismo para todos los AINE. En realidad, algunos fueron retirados del ción de droxicam o de piroxicam por vía oral a mercado en los años setenta y ochenta por este ratas, los metabolitos que aparecen en orina no motivo (ibufenac, fenclofenac y benoxaprofeno). son los mismos con ambos fármacos; esto indica- Recientemente en España la Comisión Nacional ría que el metabolismo (probablemente hepático) de Farmacovigilancia recomendó la retirada del no es el mismo y que, por tanto, no se puede mercado del bendazac (Bendalina®), un AINE que, hablar de una equivalencia farmacocinética (y toxi- sin una eficacia clínica bien demostrada, se utili- cológica) absoluta entre los dos fármacos.
    [Show full text]
  • Narcotic Drugs and Psychotropic Substances (Control) Act
    LAWS OF GUYANA Narcotic Drugs and Psychotropic Cap. 35:11 3 Substances (Control) CHAPTER 35:11 NARCOTIC DRUGS AND PSYCHOTROPIC SUBSTANCES (CONTROL) ACT ARRANGEMENT OF SECTIONS PART I PRELIMINARY SECTION 1. Short title. 2. Interpretation. PART II PROHIBITION OF POSSESSION OF AND TRAFFICKING IN NARCOTICS AND CULTIVATION OF CERTAIN PLANTS 3. Definitions for Part II. 4. Penalty for possession of narcotic. 5. Penalty for trafficking in narcotic. 6. Penalty for supply, etc., of narcotic to child or young person if death results from consumption or administration of it. 7. Penalty for bringing into prison or taking out of prison, etc., of a narcotic. 8. Penalty for cultivation of certain plants. 9. Procedure for purposes of section 8(2) to (6). 10. Power of entry in respect of State or Government lands. 11. Power of destruction of prohibited plants. 12. Penalty for certain other acts connected with narcotics. 13. Certain prescriptions to be unlawful. 14. Penalty for receiving additional narcotic or prescription without disclosure of earlier receipt. 15. Removal of name from register. L.R.O. 3/1998 LAWS OF GUYANA 4 Cap. 35:11 Narcotic Drugs and Psychotropic Substances (Control) PART III NARCOTICS IN TRANSIT SECTION 16. Definitions for Part III. 17. Prohibition against sending narcotics by post. 18. Narcotics in transit. 19. Control of Comptroller over narcotics brought into Guyana in transit. 20. Tampering with narcotics in transit. 21. Diversion in Guyana of narcotics in transit. 22. Variations in export authorisation, import authorisation or diversion certificate granted in country other than Guyana. PART IV LICENCES 23. Grant and renewal of licences.
    [Show full text]